Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Halozyme (HALO)

Halozyme Therapeutics Elects James Daly to Board of Directors

Neutral Impact 2 of 5 leadership Written later

Halozyme Therapeutics elected James Daly to its Board of Directors on September 28, 2026, disclosed in a filing dated September 30, 2026. Mr. Daly was placed in the class of directors with terms ending at the 2029 annual meeting and was not initially assigned to any Board committee.

Key points

  • Board election date: September 28, 2026
  • Term ends at the company's annual meeting of stockholders in 2029
  • Not initially assigned to any Board committee
  • Compensated under the non-employee director program; no related person transactions or election arrangements disclosed

The filing

CompanyHalozyme (HALO)
Form8-K, current report
Filed with the SECSep 30, 2026, 4:20 PM ET
Accession number0001159036-26-000128

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.